Luxembourg spin-off gets funding boost for neurodegenerative research
The Luxembourg Government is to provide funding for a research project on neurodegenerative diseases led by the first true spin-off from the University of Luxembourg, Axoglia Therapeutics. The agreement, which will channel €795,000 in government funding into the project, was signed on 18 July. Private investors are also expected to provide around €300,000. The project is an attempt to develop a new family of innovative molecules that can be used to treat neurodegenerative diseases and inflammations of the nervous system, such as those found in Alzheimer's patients. 'As Economics Minister, but in this case particularly as the founder of the 'Luxembourg Alzheimer's Association', it is particularly important to be able to support such a promising project,' said Jeannot Krecké after the signing. Axoglia Therapeutics was founded following the discovery of a particularly promising molecule by researchers from the University of Luxembourg, who were working with France's National Centre for Scientific Research (CNRS) and the Louis Pasteur University in Strasbourg. The molecule's properties suggested that it could be used to treat diseases such as Multiple Sclerosis, Alzheimer's and Parkinson's. A cure for diseases affecting the central nervous system has so far eluded scientists. The medicines administered by doctors provide pain relief or slow down the speed at which the disease takes hold. The molecule that Axoglia Therapeutics will now investigate appears to have the potential to stop the worsening of a disease, and even to repair the parts of the nervous system that have already been damaged.
Countries
Luxembourg